Compare · CGC vs XXII
CGC vs XXII
Side-by-side comparison of Canopy Growth Corporation (CGC) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 8.6x XXII ($332.0M).
- Over the past year, CGC is down 36.5% and XXII is down 99.8% - CGC leads by 63.3 points.
- CGC has been more active in the news (4 items in the past 4 weeks vs 2 for XXII).
- CGC has more recent analyst coverage (19 ratings vs 4 for XXII).
- Company
- Canopy Growth Corporation
- 22nd Century Group Inc.
- Price
- $1.02-1.44%
- $0.52+9.16%
- Market cap
- $2.86B
- $332.0M
- 1M return
- -10.87%
- -27.02%
- 1Y return
- -36.53%
- -99.79%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 4
- 2
- Recent ratings
- 19
- 4
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest CGC
- Canopy Growth Announces Claybourne's Frosted Flyers Wins 'Best Infused Pre-Roll' at 2026 Grow Up Awards
- SEC Form SD filed by Canopy Growth Corporation
- Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
- Canopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
- Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets
- Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
- 'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign
- SEC Form 4 filed by Yanofsky Theresa
Latest XXII
- 22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes
- 22nd Century Group (Nasdaq: XXII) Expands High-Margin Pinnacle Platform With Launch of Pinnacle Pure at Major U.S. Retailers
- 22nd Century Group (Nasdaq: XXII) Ignites Major VLN® Retail Expansion in Metro New York and Northern New Jersey Under Pinnacle Brand
- 22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review
- SEC Form 10-Q filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 22nd Century Group Reports First Quarter 2026 Financial Results
- 22nd Century Group to Announce First Quarter 2026 Results on May 7, 2026
- 22nd Century Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by 22nd Century Group Inc.